EA202190495A1 - Антитела против pd-l1 человека - Google Patents

Антитела против pd-l1 человека

Info

Publication number
EA202190495A1
EA202190495A1 EA202190495A EA202190495A EA202190495A1 EA 202190495 A1 EA202190495 A1 EA 202190495A1 EA 202190495 A EA202190495 A EA 202190495A EA 202190495 A EA202190495 A EA 202190495A EA 202190495 A1 EA202190495 A1 EA 202190495A1
Authority
EA
Eurasian Patent Office
Prior art keywords
seq
against human
fragments
antibodies against
antibodies
Prior art date
Application number
EA202190495A
Other languages
English (en)
Inventor
Лэй Фан
Юаньюань Ян
Чжэнъи Ван
Бинши Гуо
Фэйфэй Цуй
Original Assignee
Ай-Маб Биофарма Юэс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ай-Маб Биофарма Юэс Лимитед filed Critical Ай-Маб Биофарма Юэс Лимитед
Publication of EA202190495A1 publication Critical patent/EA202190495A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложены полноразмерные антитела против PD-L1 человека или их фрагменты. В различных примерах указанные антитела или их фрагменты содержат VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 и VL CDR3, выбранные из групп последовательностей SEQ ID NO: 35-42, SEQ ID NO: 43-51, SEQ ID NO: 52-66, SEQ ID NO: 67-79, SEQ ID NO: 80-88 и SEQ ID NO: 89-102 соответственно, или варианты каждой из указанных последовательностей. Кроме того, предложены способы применения указанных антител или их фрагментов для лечения и диагностики заболеваний, таких как рак и инфекционные заболевания.
EA202190495A 2019-04-26 2020-04-26 Антитела против pd-l1 человека EA202190495A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019084468 2019-04-26
PCT/CN2020/087019 WO2020216379A1 (en) 2019-04-26 2020-04-26 Human pd-l1 antibodies

Publications (1)

Publication Number Publication Date
EA202190495A1 true EA202190495A1 (ru) 2022-02-03

Family

ID=72940614

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190495A EA202190495A1 (ru) 2019-04-26 2020-04-26 Антитела против pd-l1 человека

Country Status (14)

Country Link
US (1) US11208486B2 (ru)
EP (1) EP3833691A4 (ru)
JP (1) JP7212990B2 (ru)
KR (1) KR20210070323A (ru)
CN (1) CN112996815B (ru)
AU (1) AU2020261961B2 (ru)
BR (1) BR112021005365A2 (ru)
CA (1) CA3112681A1 (ru)
EA (1) EA202190495A1 (ru)
IL (1) IL281397B (ru)
MX (1) MX2021004897A (ru)
SG (1) SG11202103000WA (ru)
WO (1) WO2020216379A1 (ru)
ZA (1) ZA202101523B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023187460A1 (en) * 2022-04-01 2023-10-05 Mabtree Biologics Ag Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function
WO2024104373A1 (en) * 2022-11-15 2024-05-23 I-Mab Biopharma Co., Ltd. Anti-pd-l1 nanobodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
CN108997498A (zh) * 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
BR112015007672A2 (pt) * 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
BR112018009064A8 (pt) * 2015-11-17 2019-02-26 Jiangsu Hengrui Medicine Co anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
JP7148414B2 (ja) 2016-06-29 2022-10-05 チェックポイント セラピューティクス，インコーポレイテッド Ｐｄ－ｌ１特異的抗体およびそれを使用する方法
EP3554542A1 (en) 2016-12-19 2019-10-23 H. Hoffnabb-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
US20200148785A1 (en) 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
EP3612565A4 (en) 2017-04-18 2021-06-16 R-Pharm Overseas, Inc. ANTI-PD-L1 ANTIBODIES AND USES THEREOF
CA3068929A1 (en) 2017-07-06 2019-01-10 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
SG11202001654TA (en) 2017-10-10 2020-03-30 Numab Therapeutics AG Antibodies targeting pdl1 and methods of use thereof
JP2021514649A (ja) 2018-03-01 2021-06-17 ブレイエ・ユニバージテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｔｅｉｔ Ｂｒｕｓｓｅｌ ヒトｐｄ−ｌ１結合免疫グロブリン

Also Published As

Publication number Publication date
CN112996815A (zh) 2021-06-18
SG11202103000WA (en) 2021-04-29
MX2021004897A (es) 2021-06-18
AU2020261961B2 (en) 2022-07-07
CN112996815B (zh) 2024-02-20
KR20210070323A (ko) 2021-06-14
AU2020261961A1 (en) 2021-04-22
ZA202101523B (en) 2022-06-29
JP2022511311A (ja) 2022-01-31
EP3833691A4 (en) 2022-05-18
JP7212990B2 (ja) 2023-01-26
WO2020216379A1 (en) 2020-10-29
BR112021005365A2 (pt) 2021-11-16
IL281397A (en) 2021-04-29
CA3112681A1 (en) 2020-10-29
US20210309747A1 (en) 2021-10-07
EP3833691A1 (en) 2021-06-16
US11208486B2 (en) 2021-12-28
IL281397B (en) 2022-04-01

Similar Documents

Publication Publication Date Title
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
CO2018013500A2 (es) Anticuerpos anti-pd-l1 y usos de los mismos
EA201991099A1 (ru) Антитела против cd73 и их применение
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
JP2018501197A5 (ru)
MD4716B1 (ru) Антитела анти-LAG3 и антигенсвязывающие фрагменты
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени
WO2015200806A3 (en) Humanized anti-tau antibodies
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
EA034770B8 (ru) Человеческие антитела к pd-1
RU2014143784A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
NZ610734A (en) Human antibodies to the glucagon receptor
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
MA40913A (fr) Conjugués anticorps-médicament
RU2016100892A (ru) Антитела против tweakr и их применение
PE20130580A1 (es) Proteinas terapeuticas de union a dll4
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
RU2012149227A (ru) Биологические материалы, относящиеся к her3
RU2020129075A (ru) Способы лечения рака с помощью анти-PD-1-антител и анти-CTLA4-антител
PE20142322A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
JP2016530223A5 (ru)